CD44 Multi-Arm Drug Conjugates for Targeted Tumor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-cancer drugs targeting CD44 have poor targeting capability and can affect normal cells, leading to high adverse effects and difficulty in treating tumors with high CD44 expression.
Innovation Solution
A multi-branched drug conjugate with a CD44-targeted molecule and an anticancer agent, utilizing a multi-arm polymer to enhance solubility and targeting capability, specifically binding to CD44-expressing tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-cancer drugs are used to target CD44, then they can affect tumor cells, but they also affect normal cells leading to high adverse effects
Solution Approach 1:
The drug is segmented into multiple functional components: a targeting moiety (CD44-specific ligand), a linker, and a cytotoxic payload. This segmentation allows the drug to be delivered specifically to CD44-expressing tumor cells while minimizing exposure to normal cells, thereby reducing adverse effects.
Solution Approach 2:
The patent introduces a targeting moiety as an intermediary that specifically binds to CD44 receptors on tumor cells. This intermediary guides the cytotoxic payload to the intended target, preventing direct exposure of normal cells to the toxic agent and reducing adverse effects.
2Reliability
If existing anti-cancer drugs are used, then they can kill cancer cells, but they have poor targeting capability and cannot act on specific cancer cells
Solution Approach 1:
The drug conjugate exhibits local quality by concentrating the cytotoxic payload at the site of CD44-expressing tumor cells through specific binding of the targeting moiety. This localized action enhances therapeutic effect on specific cancer cells while leaving other cells unaffected.
Solution Approach 2:
The patent changes the parameter of molecular structure by designing a conjugate with specific physical and chemical properties (molecular weight, hydrophobicity, stability) that optimize its binding affinity to CD44 and its pharmacokinetic profile, thereby enhancing both targeting capability and therapeutic effect.
3Quantity of substance
If multi-arm polymer is used to increase drug loading, then water solubility and drug loading are improved, but targeting capability remains poor
Solution Approach 1:
The patent creates a composite material consisting of a multi-arm polymer core, targeting moieties, linkers, and cytotoxic payloads. This composite structure combines the advantages of high drug loading capacity (from multi-arm polymer) with specific targeting capability (from CD44-specific ligands), resolving the contradiction between quantity and reliability.
Solution Approach 2:
The multi-arm polymer conjugate structure serves multiple functions simultaneously: it provides high drug loading capacity through its branched architecture, ensures water solubility through hydrophilic polymer chains, and enables specific targeting through attached CD44-specific ligands. This multi-functionality resolves the contradiction by making the single structure capable of all required functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate achieves higher concentration in target tissues, improving therapeutic effects while reducing toxicity and enhancing treatment efficacy for tumors with high CD44 expression.
Implementation Method 1
specifically binding to CD44-expressing tumor cells
Data Source
AI summary
Disclosed is a class of multi-branched drug conjugates capable of specifically targeting CD44. The class of compounds specifically binds to CD44, and may target tumor cells and tissues having high expression of CD44, so that the concentration of the conjugate in a target tissue is high, the clinical treatment effect thereof is improved, and toxicity is reduced. The compound of the present invention is suitable for treating all tumors having high expression of CD44, comprising but not limited to gastric cancer, pancreatic cancer, small cell lung cancer, colon cancer, breast cancer, lung adenocarcinoma, liver cancer, nasopharyngeal carcinoma, malignant glioma, lymphoma, renal carcinoma, ovarian cancer, head and neck cancer, squamous cell carcinoma, and the like.